title: Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil.
abstract: BACKGROUNDS AND METHODS: A higher degree of clinical efficacy with olmesartan compared with other angiotensin receptor blockers, has been reported by several sources. In this study of 31 examples of cases of essential hypertension, Holter electrocardiogram, ambulatory blood pressure monitoring and pulse wave velocity (PWV) measurements were performed before and after substituting olmesartan 20 mg for candesartan 8 mg antihypertensive drug therapy.
  
  
  RESULTS
  Following the therapeutic change, daily average systolic and diastolic blood pressures were decreased by 6.7 +/- 9.3 mmHg and 3.6 +/- 8.3 mmHg, respectively, with olmesartan 20 mg; PWV was also significantly decreased. Holter electrocardiogram heart rate variability spectral analysis demonstrated that none of the very low frequency (VLF), high frequency (HF) and low frequency (LF)/HF components were significantly altered. However, a significant correlation was observed between the LF/HF component and blood pressure difference, when blood pressure and heart rate variability components in each individual case were studied.
  
  
  CONCLUSIONS
  This study shows that olmesartan has a stronger antihypertensive effect in comparison to candesartan, and does not generate reflex sympathoexcitatory activity.
authors.affiliation: Department of Internal Medicine, School of Medicine, Teikyo University, Teikyo, Japan.
authors.forename: Taiji
authors.initials: T
authors.lastname: Furukawa
authors.forename: Taketo
authors.initials: T
authors.lastname: Hatsuno
authors.forename: Yasunari
authors.initials: Y
authors.lastname: Ueno
authors.forename: Kensuke
authors.initials: K
authors.lastname: Nagaoka
authors.forename: Yuji
authors.initials: Y
authors.lastname: Watari
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yamakawa
authors.forename: Toshio
authors.initials: T
authors.lastname: Sagawa
authors.forename: Takaaki
authors.initials: T
authors.lastname: Isshiki
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D018660:Blood Pressure Monitoring, Ambulatory; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D000068557:Olmesartan Medoxomil; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D007093:Imidazoles; D013777:Tetrazoles; D000068557:Olmesartan Medoxomil; C077793:candesartan cilexetil